Ziihera moves into first-line HER2-positive cancer treatment after pivotal Phase 3 results
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer. See how the approval could reshape treatment and Zymeworks growth.
Pharma & Biotech